<p>药明康德（NASDAQ:MVIS - 获取免费报告）于周三发布了季度财报。这家电子制造商报告本季度每股收益为（$0.12），低于分析师一致预期的（$0.05），差距为（$0.07），FiscalAI 报道。药明康德的股本回报率为负的 131.03%，净利润率为负的 3,354.08%。该公司本季度的收入为 22 万美元，而一致预期为 300 万美元。</p>
<h2>药明康德价格表现</h2>
<ul>
<li>你发誓永远不会买的三只便士股票（但你还是会查看）</li>
</ul>
<p>周三交易时段，MVIS 股价下跌 0.01 美元，报 0.78 美元。该股票交易量为 4,007,852 股，而其平均交易量为 4,059,544 股。该公司的市值为 2.3815 亿美元，市盈率为 -2.11，贝塔值为 1.21。药明康德的 52 周低点为 0.65 美元，52 周高点为 1.73 美元。该公司的 50 日移动平均线为 0.84 美元，200 日移动平均线为 1.01 美元。</p>
<h2>分析师设定新目标价</h2>
<p>几位股票分析师对该股发表了评论。D. Boral Capital 在 1 月 27 日的报告中重申了 “买入” 评级，并对药明康德的股票设定了 3.00 美元的目标价。Weiss Ratings 在 12 月 29 日的研究报告中重申了对药明康德的 “卖出（d-）” 评级。两位投资分析师给予该股 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股目前的平均评级为 “持有”，一致目标价为 2.50 美元。</p>
<ul>
<li>药明康德在空头挤压后能否保持势头？</li>
</ul>
<p><strong>查看我们最新的 MVIS 股票报告</strong></p>
<h2>机构投资者对药明康德的看法</h2>
<p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。NewEdge Advisors LLC 在第一季度收购了药明康德的新股份，价值约 56,000 美元。Focus Partners Wealth 在第一季度购买了药明康德的新股份，价值约 32,000 美元。摩根大通在第二季度将其在药明康德的持仓增加了 20.0%。摩根大通目前拥有 136,739 股该电子制造商的股票，价值 156,000 美元，此前在此期间又购买了 22,824 股。Rhumbline Advisers 在第二季度将其在药明康德的持仓增加了 17.2%。Rhumbline Advisers 目前拥有 330,919 股该电子制造商的股票，价值 377,000 美元，此前在此期间又购买了 48,588 股。最后，保诚金融公司在第二季度将其在药明康德的持仓增加了 77.4%。保诚金融公司目前拥有 30,520 股该电子制造商的股票，价值 35,000 美元，此前在上个季度又收购了 13,315 股。机构投资者持有该公司 30.90% 的股份。</p>
<h2>关于药明康德</h2>
<p>（获取免费报告）</p>
<p>药明康德，Inc NASDAQ: MVIS 是一家专注于激光扫描和传感解决方案的科技公司。成立于 1993 年，总部位于华盛顿州雷德蒙德，药明康德开发了其专有的 PicoP® 扫描技术，该技术集成了微型激光器和微电机械系统（MEMS）镜子，以创建高分辨率投影显示和三维传感系统。多年来，该公司建立了一系列专注于精密光学和基于激光的信号处理的专利和知识产权。</p>
<p>药明康德产品的核心是其显示平台，该平台支持紧凑、节能的投影，适用于增强现实（AR）头戴设备、汽车环境中的抬头显示（HUD）以及消费电子应用，如微型投影仪。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，胜过药明康德</li>
<li>CSE: ALEN.U 正在瞄准快速增长的数字健康市场</li>
<li>新发现富铜的 “克拉肯” 区域</li>
<li>1,500 家银行刚刚将你的银行账户交给了美联储</li>
<li>你的名字尚未在我们的保护名单上</li>
<li>白银支付 20% 股息，外加 68% 股份增值</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVZJUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVZJUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
<p>在你考虑药明康德之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而药明康德并不在名单上。</p>
<p>虽然药明康德目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

维视图像

<p>Microvision（纳斯达克代码：MVIS）报告每股收益为（$0.12），低于预期$0.07。该公司的股本回报率为负的 131.03%，收入为 22 万美元，远低于 300 万美元的预期。股价下跌至$0.78，市值为 2.3815 亿美元。分析师的评级意见不一，普遍目标价为$2.50。机构投资者持有 30.90% 的股份。Microvision 专注于激光扫描和传感解决方案，重点开发高分辨率投影显示和 3D 传感系统</p>

<p>Microvision (NASDAQ:MVIS - Get Free Report) issued its quarterly earnings results on Wednesday. The electronics maker reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.07), FiscalAI reports. Microvision had a negative return on equity of 131.03% and a negative net margin of 3,354.08%.The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $3.00 million.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:MVIS - 获取免费报告）于周三发布了季度财报。这家电子制造商报告本季度每股收益为（$0.12），低于分析师一致预期的（$0.05），差距为（$0.07），FiscalAI 报道。药明康德的股本回报率为负的 131.03%，净利润率为负的 3,354.08%。该公司本季度的收入为 22 万美元，而一致预期为 300 万美元。</p>
</div><h2>Microvision Price Performance</h2>
<div class="lb-trans"><h2>药明康德价格表现</h2>
</div><ul>
<li>The 3 Penny Stocks You Swore You’d Never Buy (But You’ll Check Anyway)</li>
</ul>
<div class="lb-trans"><ul>
<li>你发誓永远不会买的三只便士股票（但你还是会查看）</li>
</ul>
</div><p>Shares of MVIS traded down $0.01 during trading hours on Wednesday, hitting $0.78. 4,007,852 shares of the stock were exchanged, compared to its average volume of 4,059,544. The firm has a market capitalization of $238.15 million, a P/E ratio of -2.11 and a beta of 1.21. Microvision has a fifty-two week low of $0.65 and a fifty-two week high of $1.73. The business has a 50-day moving average of $0.84 and a 200-day moving average of $1.01.</p>
<div class="lb-trans"><p>周三交易时段，MVIS 股价下跌 0.01 美元，报 0.78 美元。该股票交易量为 4,007,852 股，而其平均交易量为 4,059,544 股。该公司的市值为 2.3815 亿美元，市盈率为 -2.11，贝塔值为 1.21。药明康德的 52 周低点为 0.65 美元，52 周高点为 1.73 美元。该公司的 50 日移动平均线为 0.84 美元，200 日移动平均线为 1.01 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several equities analysts have commented on the stock. D. Boral Capital reissued a &#34;buy&#34; rating and issued a $3.00 target price on shares of Microvision in a report on Tuesday, January 27th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Microvision in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus price target of $2.50.</p>
<div class="lb-trans"><p>几位股票分析师对该股发表了评论。D. Boral Capital 在 1 月 27 日的报告中重申了 “买入” 评级，并对药明康德的股票设定了 3.00 美元的目标价。Weiss Ratings 在 12 月 29 日的研究报告中重申了对药明康德的 “卖出（d-）” 评级。两位投资分析师给予该股 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股目前的平均评级为 “持有”，一致目标价为 2.50 美元。</p>
</div><ul>
<li>Will MicroVision Maintain Its Momentum After the Short Squeeze?</li>
</ul>
<div class="lb-trans"><ul>
<li>药明康德在空头挤压后能否保持势头？</li>
</ul>
</div><p><strong>View Our Latest Stock Report on MVIS</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 MVIS 股票报告</strong></p>
</div><h2>Institutional Investors Weigh In On Microvision</h2>
<div class="lb-trans"><h2>机构投资者对药明康德的看法</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC acquired a new stake in Microvision during the first quarter worth approximately $56,000. Focus Partners Wealth bought a new position in shares of Microvision during the 1st quarter worth approximately $32,000. JPMorgan Chase &amp; Co. grew its position in shares of Microvision by 20.0% during the 2nd quarter. JPMorgan Chase &amp; Co. now owns 136,739 shares of the electronics maker's stock worth $156,000 after buying an additional 22,824 shares during the period. Rhumbline Advisers grew its position in shares of Microvision by 17.2% during the 2nd quarter. Rhumbline Advisers now owns 330,919 shares of the electronics maker's stock worth $377,000 after buying an additional 48,588 shares during the period. Finally, Prudential Financial Inc. increased its stake in shares of Microvision by 77.4% in the 2nd quarter. Prudential Financial Inc. now owns 30,520 shares of the electronics maker's stock valued at $35,000 after acquiring an additional 13,315 shares in the last quarter. Institutional investors own 30.90% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。NewEdge Advisors LLC 在第一季度收购了药明康德的新股份，价值约 56,000 美元。Focus Partners Wealth 在第一季度购买了药明康德的新股份，价值约 32,000 美元。摩根大通在第二季度将其在药明康德的持仓增加了 20.0%。摩根大通目前拥有 136,739 股该电子制造商的股票，价值 156,000 美元，此前在此期间又购买了 22,824 股。Rhumbline Advisers 在第二季度将其在药明康德的持仓增加了 17.2%。Rhumbline Advisers 目前拥有 330,919 股该电子制造商的股票，价值 377,000 美元，此前在此期间又购买了 48,588 股。最后，保诚金融公司在第二季度将其在药明康德的持仓增加了 77.4%。保诚金融公司目前拥有 30,520 股该电子制造商的股票，价值 35,000 美元，此前在上个季度又收购了 13,315 股。机构投资者持有该公司 30.90% 的股份。</p>
</div><h2>About Microvision</h2>
<div class="lb-trans"><h2>关于药明康德</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MicroVision, Inc NASDAQ: MVIS is a technology company specializing in laser scanning and sensing solutions. Founded in 1993 and headquartered in Redmond, Washington, MicroVision develops its proprietary PicoP® scanning technology, which integrates miniature lasers and microelectromechanical systems (MEMS) mirrors to create high-resolution projection displays and three-dimensional sensing systems. Over the years, the company has built a portfolio of patents and intellectual property focused on precision optics and laser-based signal processing.</p>
<div class="lb-trans"><p>药明康德，Inc NASDAQ: MVIS 是一家专注于激光扫描和传感解决方案的科技公司。成立于 1993 年，总部位于华盛顿州雷德蒙德，药明康德开发了其专有的 PicoP® 扫描技术，该技术集成了微型激光器和微电机械系统（MEMS）镜子，以创建高分辨率投影显示和三维传感系统。多年来，该公司建立了一系列专注于精密光学和基于激光的信号处理的专利和知识产权。</p>
</div><p>At the core of MicroVision's offerings is its display platform, which enables compact, energy-efficient projection for augmented reality (AR) headsets, head-up displays (HUDs) in automotive environments, and consumer electronics applications such as pico projectors.</p>
<div class="lb-trans"><p>药明康德产品的核心是其显示平台，该平台支持紧凑、节能的投影，适用于增强现实（AR）头戴设备、汽车环境中的抬头显示（HUD）以及消费电子应用，如微型投影仪。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Microvision</li>
<li>CSE: ALEN.U is targeting a fast-growing digital wellness market</li>
<li>New Copper-Rich “Kraken” Zone Discovered</li>
<li>1,500 Banks Just Handed the Fed Your Bank Account</li>
<li>Your name isn't on our protected list yet</li>
<li>Silver paying 20% dividend. Plus 68% share gains</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过药明康德</li>
<li>CSE: ALEN.U 正在瞄准快速增长的数字健康市场</li>
<li>新发现富铜的 “克拉肯” 区域</li>
<li>1,500 家银行刚刚将你的银行账户交给了美联储</li>
<li>你的名字尚未在我们的保护名单上</li>
<li>白银支付 20% 股息，外加 68% 股份增值</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVZJUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=MVIS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Microvision Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
</div><p>Before you consider Microvision, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑药明康德之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microvision wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而药明康德并不在名单上。</p>
</div><p>While Microvision currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然药明康德目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

维视图像（NASDAQ:MVIS）公布了财报，收益每股比预期低 0.07 美元